Risk of Coronary Heart Disease in Women With Polycystic Ovary Syndrome
Carotid Artery Diseases
Polycystic Ovary Syndrome
|Study Start Date:||September 2000|
|Study Completion Date:||August 2006|
|Primary Completion Date:||August 2006 (Final data collection date for primary outcome measure)|
The risk of coronary heart disease (CHD) is lower in women than men. This has been attributed to differences in sex hormones, insulin sensitivity, and environmental factors. Women with Polycystic Ovary syndrome have characteristics, including anovulation, hyperandrogenism and insulin resistance, which suggests a male risk factor profile. The study tests the hypothesis that women with PCOS are at greater risk of coronary heart disease than non-PCOS women. When the study was initiated in 1991, there were few data available on long-term followup of women with PCOS.
Beginning in 1991, the investigators tested the hypothesis that women with PCOS, who comprise 5 percent of the female population, are at greater risk of coronary heart disease than non-PCOS women. They traced and followed-up, via telephone interviews, 244 women with PCOS and 244 age-matched neighborhood controls. They then conducted a cross-sectional study to assess reproductive, hormonal and other coronary heart disease risk factors in the women with PCOS compared with the controls. Evaluation consisted of an office visit to determine total cholesterol, triglycerides, HDL cholesterol, fasting and two hour glucose and insulin, blood pressure, lifetime cigarette smoking, alcohol intake, reproductive history, lifetime medication usage, family history of PCOS, and serum hormone concentrations. At this evaluation, a physician diagnosis of PCOS from history, physical exam, and hormone studies was made. In addition, information on the number of pregnancies, number of live births, menstrual history, and history of surgical or natural menopause was obtained. Women with evidence of thyroid, adrenal or pituitary disease were excluded.
The grant was renewed in 1996 to determine whether women with PCOS have evidence of an increased prevalence rate of subclinical atherosclerosis. Within the PCOS population the investigators performed five studies to further determine risk factors for subclinical atherosclerosis. First, they evaluated the relationship between PCOS and subclinical atherosclerosis as measured by carotid ultrasound. In this study, they determined whether women, thirty years of age or older with PCOS, had a higher prevalence of subclinical atherosclerosis than age-matched control women. Second, they evaluated the relationship between PCOS and subclinical vascular disease as measured by brachial artery flow mediated vasodilation. They determined whether PCOS cases had lower brachial artery flow mediated vasodilation than controls, and whether the distribution of flow mediated vasodilation was related to the extent of carotid artery wall thickness and plaque. Third, they evaluated whether subclinical atherosclerosis and vascular disease were related to the following cardiovascular risk factors within PCOS cases and controls: HDL cholesterol, LDL cholesterol, triglycerides, insulin, systolic and diastolic blood pressure and testosterone, waist-to-hip ratio and body mass index (BMI). Fourth, they assessed differences in body composition between PCOS cases and control women, including intra-abdominal fat as measured by computed tomography (CT) of the abdomen and sagittal diameter, and percent body fat as measured by dual energy x-ray absorptiometry (DEXA). They evaluated the relationship between subclinical atherosclerosis and body composition separately for cases and for controls. Previous studies had clearly shown that PCOS women were different from obese non-PCOS women. Moreover, insulin, testosterone and coronary heart disease risk factors were also correlated with these measures using paired t-tests. Multiple regression was used to test whether PCOS cases compared to controls had an increase in intra-abdominal fat which was independent of important confounders. Fifth, they compared plasma levels of selected coagulation factors including fibrinogen and factor VII to fibrinolytic factors for PCOS cases and controls.
The study was renewed in September 2000 through August 2004 to continue follow-up.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00005459
|OverallOfficial:||Evelyn Talbott||University of Pittsburgh|